Xtant Medical Aktie News

Die Partnerschaft nutzt das Vertriebsnetz von BioHorizons, um die Verfügbarkeit der allogenen Wachstumsfaktor‑Technologie von Xtant, OsteoFactor Pro™, zu verbreitern, die BioHorizons unter der Privatmarke Prolifica™ vertreiben wird. BELGRADE, Mont., 27. Aug. 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), ein globales Medizintechnikunternehmen mit Fokus auf chirurgische...

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August 11 th, at 8:30am ET BELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions ...

BELGRADE, Mont., 4. Aug. 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), ein Medizintechnologieunternehmen mit Schwerpunkt auf chirurgischen Lösungen für Wirbelsäulen- und andere orthopädische Erkrankungen, gab heute bekannt, dass Sean Browne, CEO, Scott Neils, CFO, und Mark Schallenberger, COO, an der Canaccord Genuity 46th Annual Growth Conference teilnehmen werden, d...

Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales team BELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology com...

BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026.

BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft portfolio that is now available in pre‑shaped configurations designed to support handling, preparat...

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va.